Ceftibuten Dihydrate

CHEMBL1200985 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
446.5 g/mol
LogP
Phase
4

The dihydrate form of ceftibuten is the oral formulation of this third-generation cephalosporin, equivalent in antibacterial activity to the parent compound. It is indicated for mild to moderate respiratory and ear infections due to susceptible gram-negative bacteria. The formulation is available as capsules and oral suspension for pediatric use.

Molecular Weight

446.5000 g/mol

TPSA

218.00 Ų

Mechanism of Action

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1.O.O

InChI

InChI=1S/C15H14N4O6S2.2H2O/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19;;/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25);2*1H2/b6-1-;;/t10-,13-;;/m1../s1

Molecular Formula

C15H18N4O8S2

HBD / HBA

6 / 12

Rotatable Bonds

6

Heavy Atoms

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The dihydrate form of ceftibuten is the oral formulation of this third-generation cephalosporin, equivalent in antibacterial activity to the parent compound. It is indicated for mild to moderate respiratory and ear infections due to susceptible gram-negative bacteria. The formulation is available as capsules and oral suspension for pediatric use.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Ceftibuten Dihydrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200985. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5282241. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.